Published in
Elsevier, Lung Cancer, (108), p. 150-153, 2017
DOI: 10.1016/j.lungcan.2017.03.007
Links
Tools
Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial
Journal article published in 2017 by
Ben J. Slotman,
Corinne Faivre-Finn 
,
Harm van Tinteren ,
Astrid Keijser,
John Praag,
Joost Knegjens,
Matthew Hatton,
Iris van Dam,
Annija van der Leest,
Bart Reymen,
Jos Stigt,
Kate Haslett,
Devashish Tripathi,
Egbert F. Smit,
Suresh Senan
,
Harm van Tinteren ,
Astrid Keijser,
John Praag,
Joost Knegjens,
Matthew Hatton,
Iris van Dam,
Annija van der Leest,
Bart Reymen,
Jos Stigt,
Kate Haslett,
Devashish Tripathi,
Egbert F. Smit,
Suresh Senan
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
In ES-SCLC patients with residual intrathoracic disease after first-line chemotherapy, the addition of thoracic radiotherapy reduces the risk of intrathoracic recurrence, and improves 2-year survival. To identify patient subgroups for future trials investigating higher dose (extra)thoracic radiotherapy, we investigated the prognostic importance of number and sites of metastases in patients included in the CREST trial.